Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-08-23
2010-12-21
Bernhardt, Emily (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S319000, C544S360000, C544S364000, C546S194000, C546S268100, C546S278400, C546S279100
Reexamination Certificate
active
07855290
ABSTRACT:
A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity.[R1represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2and R3represent hydrogen; R4, R5, R6, and R7may be the same or different and each represents hydrogen, halogen, C1-6alkyl or the like; R8represents hydrogen or the like; R9represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.]
REFERENCES:
patent: 2004/0053908 (2004-03-01), Funahashi et al.
patent: 2004/0242603 (2004-12-01), Fujiwara et al.
patent: 2005/0245530 (2005-11-01), Borzilleri
patent: 2005/0277652 (2005-12-01), Matsushima et al.
patent: 1 411 046 (2004-04-01), None
patent: 1 473 043 (2004-11-01), None
patent: 1 719 762 (2006-11-01), None
patent: 1 719 763 (2006-11-01), None
patent: 1 889 836 (2008-02-01), None
patent: WO-02/32872 (2002-04-01), None
patent: WO-02/096361 (2002-12-01), None
patent: WO-03/000660 (2003-01-01), None
patent: WO-03/087026 (2003-10-01), None
patent: WO-03/099771 (2003-12-01), None
patent: WO-2004/076412 (2004-09-01), None
patent: WO-2004/089286 (2004-10-01), None
patent: WO-2005/004607 (2005-01-01), None
patent: WO-2005-004808 (2005-01-01), None
patent: WO-2005/005378 (2005-01-01), None
patent: WO-2005/005389 (2005-01-01), None
patent: WO-2005/010005 (2005-02-01), None
patent: WO-2005/016920 (2005-02-01), None
patent: WO-2005/030140 (2005-04-01), None
patent: WO-2005/040154 (2005-05-01), None
patent: WO-2005/082854 (2005-09-01), None
patent: WO-2005/082855 (2005-09-01), None
patent: WO 2005/117867 (2005-12-01), None
patent: WO-2006/004636 (2006-01-01), None
patent: WO-2006/014325 (2006-02-01), None
patent: WO-2007/023768 (2007-03-01), None
Office Actions (dated Oct. 21, 2008 and Dec. 12, 2007) in related patent application No. 1024/2006 in Pakistan, in English.
Office Action (dated Oct. 21, 2008) in related patent application No. 375/2008 in Pakistan, in English.
Christine Ting Ting To et al.; The roles of hepatocyte growth . . . , Oncology Reports 5: 1013-1024, 1998.
Eliot M. Rosen et al.; Scatter Factor and Angiogenesis, Advances in Cancer Research, 67, pp. 257-279, 1995.
N. Maehara et al.; NK4, a four-kringle antagonist . . . , British Journal of Cancer, 84, pp. 864-873, 2001.
Kunio Matsumoto et al.; NK4 (HGF-antagonist/angiogenesis inhibitor) . . . , Cancer Sci., 94, pp. 321-327, 2003.
Matthias Ebert et al., Coexpression of thec-met. . . , Cancer Research 54, pp. 5775-5778, 1994.
Hiroki Kumiyasu et al.; Frequent amplification . . . , Biochemical and Biophysical Research Communications, vol. 189, No. 1, pp. 227-232, Nov. 30, 1992.
Chi Liu et al., Overexpression ofc-met. . . , Oncogene, 7, pp. 181-185, 1992.
Rola A. D. Choussoub et al.; Expression ofc-met. . . , Cancer, 82, pp. 1513-1520, 1998.
Louis L. Pisters et al., C-met Proto-Oncogene Expression, The Journal of Urology, vol. 154, pp. 293-298, Jul. 1995.
Iwao Takanami et al., Hepatocyte Growth Factor . . . , Oncology, 53, pp. 392-397, 1996.
Laura Schmidt et al., Novel mutations of the MET . . . , Oncogene, 14, pp. 2343-2350, 1999.
Shahriar Koochekpour et al., Met and Hepatocyte Growth . . . , Cancer Research, 57, pp. 5391-5398, 1997.
Janos Tanyi et al., Evaluation of the Tyrosine . . . , Pathology Oncology Research, 5, pp. 187-191, 1999.
Yoshitaka Imaizumi et al., Expression of the c-Met . . . , Clinical Cancer Research, vol. 9, pp. 181-187, 2003.
Joachim Ulrich, “Crystallization-4.Crystal Characteristics”, Kirk-Othmer Encyclopedia of Chemical Technology, Aug. 2002, 7 pages.
Sudha R. Vippagunta et al., “Crystalline Solids”, Advanced Drug Delivery Reviews, 48, 2001, pp. 3-26.
Anthony R. West, “Solid Solutions”, Solid State Chemistry and its applications, 1988, pp. 358-365.
“MET tyrosine kinase inhibitors,”Nature Reviews / Drug Discovery, vol. 7, Jun. 2008, p. 469.
“E7050: A novel orally active c-Met and VEGFR-2 tyrosine kinase inhibitor exhibited potent antitumor effect and prolongation of survival in preclinical mice model”, Nakagawa et al, Nagakagawa et al., Abstract of P1-8 in Japanese Association for Molecular Target Therapy of Cancer 2008.
“E7050: A novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases”, Obaishi et al., Abstract of P1-7 in Japanese Association for Molecular Target Therapy of Cancer 2008.
Miller et al., “Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma,” Oncogene, 2006, vol. 25, pp. 409-418.
Nakagawa et al., Poster Manuscript, “E7050: A novel orally active c-Met and VEGFR-2 tyrosine kinase inhibitor exhibited potent antitumor effect and prolongation of survival in preclinical mice model.”, Proceedings of the American Association for Cancer Research 2008.
Obaishi et al., Poster Manuscript, “E7050: A novel small molecule the c-Met and VEGFR-2 tyrosine kinase.”, Proceedings of the American Association for Cancer Research 2008.
E7050: “A novel orally active c-Met and VEGFR-2 tyrosine kinase inhibitor exhibited potent antitumor effect and prolongation of survival in preclinical mice model.”, Nakagawa et al., Proceedings of the American Association for Cancer Research, vol. 49, p. 1154, #4845, 2008.
E7050: “A novel small molecule the c-Met and VEGFR-2 tyrosine kinase.”, Obaishi et al., Proceedings of the American Association for Cancer Research, vol. 49, p. 1154, #4846, 2008.
Office Action dated Dec. 3, 2008 in corresponding Russian patent application No. 2008110932, with English translation.
Office Action dated Nov. 5, 2007 in corresponding patent application No. 184/2006/4959 in Bangladesh, in English.
Funasaka Setsuo
Matsushima Tomohiro
Shirotori Shuji
Takahashi Keiko
Bernhardt Emily
Birch & Stewart Kolasch & Birch, LLP
Eisai R&D Management Co., Ltd.
LandOfFree
Pyridine derivatives and pyrimidine derivatives (3) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridine derivatives and pyrimidine derivatives (3), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridine derivatives and pyrimidine derivatives (3) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165505